Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Carter Gould - Barclays Trung Huynh - UBS Steve Scala - Cowen Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities Matt Phipps - William Blair David Risinger - Leerink Partners Akash Tewari - Jefferies James Shin - Deutsche Bank Olivia Brayer - Cantor Sean McCutchen - Raymond James Srikripa Devarakonda - Truist Securities Operator Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $2 per share a year ago.
Bristol Myers's stock pops as earnings top estimates and company raises guidance
The company says it “made important strides in the third quarter.”
Bristol Myers Stock Rises After Earnings Beat, Guidance Hike
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs
Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid as well as newer drugs like heart treatment Camzyos and cancer cell therapy Breyanzi.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Bristol-Myers Squibb, an American multinational pharmaceutical company that discovers, develops, and markets drugs for various therapeutic areas, is now a $108 billion (by market cap) Big Pharma giant. To date, BMY increased its dividend for 15 consecutive years, with a 10-year dividend growth rate of 5%. The company advanced its revenue from $15.9 billion in FY 2014 to $45 billion in FY 2023, a compound annual growth rate of 12.3%.
Bristol Myers Squibb's Q3 Earnings Are Likely To Be Strong
Bristol Myers Squibb remains undervalued with strong long-term potential, despite recent stock price declines and market skepticism about its growth prospects. The company reported strong Q2 FY2024 results, beating expectations with $12.20 billion in sales and $2.07 adjusted EPS, highlighting its growth portfolio's success. BMY's strategic focus on oncology, cardiovascular, and immunology, along with operational excellence and pipeline expansion, positions it well for future growth and recovery.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
